With over 200 validated methods and models, a facilitated access to patient samples and a world class academic and industrial network, ERBC is uniquely positioned to establish the preclinical proof-of-concept of any therapies.

Thus, by performing in vitro functional assays and custom-designed assays and assessing the therapeutic effect of the test compound in relevant animal models, ERBC converts next-generation therapeutics into validated drug candidates across almost all therapeutic areas and indications (except infectious diseases).

In addition, the company also conducts exploratory programs that allow early detection of deleterious adverse effect and toxicity induced by New Chemical Entities.

Together, these translational studies contribute to clarify the mechanism of action of the drug candidate and obviously, to improve risk-taking and decision making.